NCT04899128
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting

Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have progressed on Tykerb/lapatinib
Exclusions: 
https://ClinicalTrials.gov/show/NCT04899128